The results ofthe Phase III ADAURA trial [101]comparing 3 years of adjuvant osimertinib to placebo in patients withcompletely-resected, EGFR-mutated Stage IB-IIIA NSCLC were recently published.The 2-year DFS was statistically significant, with a clinically meaningfulimprovement in DFS in the osimertinib group (90% vs. 40%,respectively). Here, EGFR is linked to non-small cell lung carcinoma.